Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elsulfavirine + nucleoside reverse transcriptase inhibitor + integrase strand transfer inhibitor
- Development stage
- Unknown
- Lead developer
- Viriom
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Elsulfavirine + nucleoside reverse transcriptase inhibitor + integrase strand transfer inhibitor is a fixed-dose combination (FDC) therapy under development by Viriom and Ritverc for the treatment and prophylaxis of HIV-1 infection. The regimen centers on elsulfavirine (VM-1500), a long-acting non-nucleoside reverse transcriptase inhibitor (NNRTI) that acts as a prodrug for the active moiety VM-1500A. By combining elsulfavirine with a nucleoside reverse transcriptase inhibitor (NRTI) and an integrase strand transfer inhibitor (INSTI), the therapy targets two critical enzymes in the viral replication cycle: reverse transcriptase and integrase. This multi-target approach is designed to increase the genetic barrier to resistance and provide a complete, simplified dosing regimen. The combination is currently in Phase 3 clinical development, aiming to provide a robust option for both treatment-naive patients and those requiring pre-exposure prophylaxis (PrEP).
- Other names
- Elsulfavirine/NRTI/INSTI FDCElsulfavirine + NRTI + INSTI
02
Targets
Integrase allosteric pocket (HIV)Human immunodeficiency virus type 1 reverse transcriptaseCA1 (Carbonic anhydrase 1)CA2 (Carbonic Anhydrase 2)CA7 (Carbonic anhydrase VII)
Beyond the preview
Go deeper on elsulfavirine + nucleoside reverse transcriptase inhibitor + integrase strand transfer inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elsulfavirine + nucleoside reverse transcriptase inhibitor + integrase strand transfer inhibitor.